BR112012023046A2 - vacinas de vírus de febre aftosa recombinantes e seus respectivos usos - Google Patents

vacinas de vírus de febre aftosa recombinantes e seus respectivos usos

Info

Publication number
BR112012023046A2
BR112012023046A2 BR112012023046A BR112012023046A BR112012023046A2 BR 112012023046 A2 BR112012023046 A2 BR 112012023046A2 BR 112012023046 A BR112012023046 A BR 112012023046A BR 112012023046 A BR112012023046 A BR 112012023046A BR 112012023046 A2 BR112012023046 A2 BR 112012023046A2
Authority
BR
Brazil
Prior art keywords
fmdv
virus vaccines
mouth virus
recombinant foot
recombinant
Prior art date
Application number
BR112012023046A
Other languages
English (en)
Other versions
BR112012023046B1 (pt
Inventor
J Feilmeier Bradley
Audonnet Jean-Christophie
Marie Troupe Karolyn
Cox Kevin
Bublot Michel
Guo Xuan
Original Assignee
Biolex Therapeutics
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolex Therapeutics, Merial Ltd filed Critical Biolex Therapeutics
Publication of BR112012023046A2 publication Critical patent/BR112012023046A2/pt
Publication of BR112012023046B1 publication Critical patent/BR112012023046B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/517—Plant cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Abstract

vacinas de vírus de febre aftosa recombinantes e seus respectivos usos. a presente invenção engloba as vacinas ou composições de fmdv. a vacina ou composição pode ser uma composição de vacina contendo antígenos fmdv. a presente invenção também engloba vetores recombinantes que codificam e expressam antígenos fmdv, epítopos ou imunogênicos, que podem ser utilizados para proteger animais contra fmdv, em particular, ovinos, bovinos, caprinos ou suínos.
BR112012023046A 2010-03-12 2011-03-11 vacinas de vírus de febre aftosa recombinantes e seus respectivos usos BR112012023046B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31316410P 2010-03-12 2010-03-12
US36636310P 2010-07-21 2010-07-21
PCT/US2011/028115 WO2011112945A2 (en) 2010-03-12 2011-03-11 Foot and mouth disease virus recombinant vaccines and uses thereof

Publications (2)

Publication Number Publication Date
BR112012023046A2 true BR112012023046A2 (pt) 2017-07-18
BR112012023046B1 BR112012023046B1 (pt) 2020-04-07

Family

ID=43923659

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112012023046A BR112012023046B1 (pt) 2010-03-12 2011-03-11 vacinas de vírus de febre aftosa recombinantes e seus respectivos usos
BR112012023852-3A BR112012023852B1 (pt) 2010-03-12 2011-03-11 vacinas recombinantes do vírus da língua azul e usos das mesmas

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112012023852-3A BR112012023852B1 (pt) 2010-03-12 2011-03-11 vacinas recombinantes do vírus da língua azul e usos das mesmas

Country Status (15)

Country Link
US (3) US9345759B2 (pt)
EP (4) EP2545067B1 (pt)
JP (1) JP2013522300A (pt)
CN (2) CN103492410A (pt)
AR (1) AR080515A1 (pt)
AU (1) AU2011224188B2 (pt)
BR (2) BR112012023046B1 (pt)
CA (2) CA2792117C (pt)
ES (2) ES2795148T3 (pt)
IL (3) IL221781B (pt)
MA (1) MA34087B1 (pt)
NZ (2) NZ602278A (pt)
RU (1) RU2575599C2 (pt)
WO (2) WO2011112955A1 (pt)
ZA (1) ZA201206619B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101540822B1 (ko) 2007-03-27 2015-07-30 씨 레인 바이오테크놀로지스, 엘엘씨 항체 대용물 경쇄 서열을 포함하는 구축물 및 라이브러리
CA2761681A1 (en) 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
CA2842860A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies, Llc Sur-binding proteins
WO2013096828A1 (en) 2011-12-22 2013-06-27 Sea Lane Biotechnologies, Llc Surrogate binding proteins
MY174081A (en) * 2012-09-05 2020-03-09 Medicago Inc Picornavirus-like particle production in plants
US20140090108A1 (en) * 2012-09-18 2014-03-27 Freydoun Garabagi Vectors and Methods For Enhancing Recombinant Protein Expression in Plants
JP6817062B2 (ja) * 2013-03-15 2021-01-20 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 蹄疫ウイルス（ｆｍｄｖ）コンセンサスタンパク質、そのコード配列、およびそれから作成されるワクチン
AU2014243149B2 (en) * 2013-03-26 2017-11-23 The Pirbright Institute Stabilised FMDV capsids
US10872313B2 (en) 2015-06-02 2020-12-22 ROCA Medical Ltd. Method for repurposing NDC codes in a pharmaceutical database for venom derived allergens involved in venom immunotherapy
CN107073100B (zh) * 2014-09-23 2021-02-26 勃林格殷格翰动物保健美国公司 Fmdv重组疫苗及其用途
CN111944023B (zh) * 2014-11-07 2022-08-19 普莱柯生物工程股份有限公司 一种抗o型***的疫苗组合物及其制备方法和应用
US10369215B2 (en) 2015-06-02 2019-08-06 ROCA Medical Ltd. Predilution sets for distributing antigens
US10548974B2 (en) 2015-06-02 2020-02-04 ROCA Medical Ltd. Therapeutic treatment kit for allergies based on DNA profiles
WO2016202828A1 (en) * 2015-06-15 2016-12-22 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
EP3539566A1 (en) * 2015-11-23 2019-09-18 Boehringer Ingelheim Animal Health USA Inc. Fmdv and e2 fusion proteins and uses thereof
WO2017097875A1 (en) * 2015-12-08 2017-06-15 Danmarks Tekniske Universitet Kit-of-parts for use in a prime-boost vaccination strategy to protect cloven-footed animals against foot-and-mouth disease virus infection
TWI730037B (zh) * 2016-01-26 2021-06-11 日商富士軟片和光純藥股份有限公司 光硬化方法，及用於該光硬化方法之化合物和組成物
TWI760322B (zh) * 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
MA44722A (fr) 2016-04-19 2019-02-27 Csir Vlp d'orbivirus chimériques produites par des plantes
US10435695B2 (en) 2016-09-08 2019-10-08 The Government of the United States of America, as represented by the Secretary of Homeland Security Fusion protein comprising Gaussia luciferase, translation interrupter sequence, and interferon amino acid sequences
US10385319B2 (en) 2016-09-08 2019-08-20 The Governement of the United States of America, as represented by the Secretary of Homeland Security Modified foot-and-mouth disease virus 3C proteases, compositions and methods thereof
WO2019023920A1 (zh) * 2017-08-01 2019-02-07 金普诺安生物科技（苏州）有限公司 一种***病毒样颗粒疫苗及其制备方法
KR102165358B1 (ko) * 2017-12-29 2020-10-14 (주)플럼라인생명과학 구제역 바이러스 a형 백신 조성물
CN108273054B (zh) * 2018-01-25 2020-11-17 中国农业科学院兰州兽医研究所 猪***病毒O型、A型Fc多肽双价疫苗及其制备方法和应用
CN111233984B (zh) * 2018-11-29 2022-08-12 普莱柯生物工程股份有限公司 一种o型***病毒样颗粒抗原、及其疫苗组合物、制备方法和应用
BR112022024067A2 (pt) * 2020-05-27 2023-04-25 Us Agriculture Cepas vivas atenuadas de febre aftosa modificadas por desotimização e usos das mesmas

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5380831A (en) 1986-04-04 1995-01-10 Mycogen Plant Science, Inc. Synthetic insecticidal crystal protein gene
US4761373A (en) 1984-03-06 1988-08-02 Molecular Genetics, Inc. Herbicide resistance in plants
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
KR950008571B1 (ko) 1986-01-08 1995-08-03 롱쁠랑 아그로시미 할로아릴니트릴 분해 유전자, 그의 용도 및 이를 함유한 세포
IE872455L (en) 1986-09-12 1988-03-12 Lanstrase Ltd Improved recombinant expression
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5990387A (en) 1988-06-10 1999-11-23 Pioneer Hi-Bred International, Inc. Stable transformation of plant cells
NZ230375A (en) 1988-09-09 1991-07-26 Lubrizol Genetics Inc Synthetic gene encoding b. thuringiensis insecticidal protein
ES2164633T3 (es) 1989-02-24 2002-03-01 Monsanto Technology Llc Genes vegetales sinteticos y procedimiento para su preparacion.
US5879918A (en) 1989-05-12 1999-03-09 Pioneer Hi-Bred International, Inc. Pretreatment of microprojectiles prior to using in a particle gun
US5690938A (en) 1989-07-07 1997-11-25 Oravax, Inc. Oral immunization with multiple particulate antigen delivery system
GB8915572D0 (en) * 1989-07-07 1989-08-23 Natural Environment Res Use of bluetongue virus proteins as vaccine components
EP0528819A1 (en) 1990-04-18 1993-03-03 Plant Genetic Systems, N.V. Modified bacillus thuringiensis insecticidal-crystal protein genes and their expression in plant cells
US5932782A (en) 1990-11-14 1999-08-03 Pioneer Hi-Bred International, Inc. Plant transformation method using agrobacterium species adhered to microprojectiles
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
TW261517B (pt) 1991-11-29 1995-11-01 Mitsubishi Shozi Kk
EP0652965A1 (en) 1992-07-27 1995-05-17 Pioneer Hi-Bred International, Inc. An improved method of agrobacterium-mediated transformation of cultured soybean cells
DE69434624T2 (de) 1993-11-19 2006-12-14 Biotechnology Research And Development Corp., Peoria Chimäre regulatorische regionen und gen - kassetten zur genexpression in pflanzen
EP0826063A1 (en) 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
EP1537877A3 (en) 1996-10-11 2005-08-03 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US6045774A (en) 1997-01-10 2000-04-04 Epicyte Pharmaceutical Inc. J chain polypeptide targeting molecule linked to an imaging agent
US5981840A (en) 1997-01-24 1999-11-09 Pioneer Hi-Bred International, Inc. Methods for agrobacterium-mediated transformation
BR9810369A (pt) 1997-06-30 2000-09-05 Rhone Poulenc Rorer Sa Processo de transferência de ácido nucleico para o interior de um ou mais músculos estriados, in vivo, composição, ácido mucleico e campo elétrico, e, produto de combinação
US7161064B2 (en) 1997-08-12 2007-01-09 North Carolina State University Method for producing stably transformed duckweed using microprojectile bombardment
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
FR2778858B1 (fr) 1998-05-20 2000-06-16 Oreal Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
US8003772B2 (en) 1999-01-14 2011-08-23 Martek Biosciences Corporation Chimeric PUFA polyketide synthase systems and uses thereof
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
FR2810888B1 (fr) * 2000-06-29 2004-07-30 Merial Sas Vaccin contre la fievre aphteuse
US8022270B2 (en) * 2000-07-31 2011-09-20 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
JP4795619B2 (ja) 2000-07-31 2011-10-19 バイオレックス・セラピューティクス インコーポレイテッド ウキクサにおける生物学的に活性なポリペプチド類の発現
US7632983B2 (en) 2000-07-31 2009-12-15 Biolex Therapeutics, Inc. Expression of monoclonal antibodies in duckweed
WO2002020937A1 (en) 2000-09-06 2002-03-14 The Charles Machine Works, Inc. Auxiliary pipe loading device
TWI377253B (en) 2001-04-16 2012-11-21 Martek Biosciences Corp Product and process for transformation of thraustochytriales microorganisms
RU2298182C2 (ru) 2001-05-30 2007-04-27 Биолекс, Инк. Применение ряски в высокопроизводительном скрининге
RU2207877C1 (ru) * 2001-11-09 2003-07-10 Всероссийский научно-исследовательский институт экспериментальной ветеринарии им. Я.Р. Коваленко Вакцина для профилактики и лечения трихофитии крупного, мелкого рогатого скота и оленей
US6680200B2 (en) 2002-02-22 2004-01-20 Biolex, Inc. Led array for illuminating cell well plates and automated rack system for handling the same
EP1485492B1 (en) * 2002-03-19 2011-12-21 Stichting Dienst Landbouwkundig Onderzoek Gntiii (udp-n-acetylglucosamine:beta-d mannoside beta(1,4)-n-acetylglucosaminyltransferase iii) expression in plants
US7176024B2 (en) 2003-05-30 2007-02-13 Biolex, Inc. Bioreactor for growing biological materials supported on a liquid surface
US7371395B2 (en) 2003-07-24 2008-05-13 Merial Limited Vaccine formulations
WO2006073431A2 (en) 2004-06-25 2006-07-13 Merial Limited Avipox recombinants expressing foot and mouth disease virus genes
CN100582122C (zh) * 2006-05-12 2010-01-20 北京宝麦德生物医药科技有限责任公司 O型***病毒多表位粘膜免疫疫苗及其应用
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
CN101082051A (zh) * 2006-06-02 2007-12-05 广东出入境检验检疫局检验检疫技术中心 重组***病毒多肽片段及其应用
CN101121938B (zh) * 2007-03-23 2010-10-06 中国农业科学院兰州兽医研究所 一种***抗原的制备方法
CN109825517B (zh) * 2007-11-26 2023-04-14 伦敦卫生及热带医学学院 呼肠弧病毒家族病毒的疫苗病毒株的制造方法
CA2707235C (en) 2007-11-27 2013-11-19 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
WO2009128043A1 (en) * 2008-04-16 2009-10-22 Onderstepoort Biological Products Ltd Inactivated live-attenuated bluetongue virus vaccine
TW201010719A (en) * 2008-08-19 2010-03-16 Wyeth Corp Immunological composition
EP3168307B1 (en) * 2008-11-28 2020-07-15 Boehringer Ingelheim Animal Health USA Inc. Recombinant avian influenza vaccine and uses thereof
KR101786121B1 (ko) 2009-03-16 2017-10-16 디에스엠 아이피 어셋츠 비.브이. 라비린툴로바이코타문 미생물에서의 단백질 생산

Also Published As

Publication number Publication date
AU2011224188B2 (en) 2015-01-22
AR080515A1 (es) 2012-04-11
EP2544716A2 (en) 2013-01-16
US20110236420A1 (en) 2011-09-29
CA2792118C (en) 2022-07-12
US20170022255A1 (en) 2017-01-26
CN103687614B (zh) 2018-06-08
EP2944322A2 (en) 2015-11-18
US9345759B2 (en) 2016-05-24
EP2545067B1 (en) 2016-11-30
RU2012143624A (ru) 2014-04-20
EP2944322A3 (en) 2015-12-16
ZA201206619B (en) 2013-05-29
AU2011224188A1 (en) 2012-09-27
ES2795148T3 (es) 2020-11-20
EP2544716B1 (en) 2020-01-01
CN103492410A (zh) 2014-01-01
MA34087B1 (fr) 2013-03-05
RU2575599C2 (ru) 2016-02-20
EP3093025B1 (en) 2018-08-01
WO2011112955A1 (en) 2011-09-15
NZ702145A (en) 2016-03-31
WO2011112945A2 (en) 2011-09-15
CA2792118A1 (en) 2011-09-15
IL221781B (en) 2018-12-31
WO2011112945A3 (en) 2011-11-10
CA2792117A1 (en) 2011-09-15
IL263253B (en) 2020-07-30
BR112012023852B1 (pt) 2020-11-10
EP2545067A1 (en) 2013-01-16
ES2617743T3 (es) 2017-06-19
IL263249B (en) 2020-05-31
CN103687614A (zh) 2014-03-26
CA2792117C (en) 2016-09-20
BR112012023046B1 (pt) 2020-04-07
BR112012023852A2 (pt) 2017-03-21
EP2944322B1 (en) 2018-01-17
US20110236416A1 (en) 2011-09-29
JP2013522300A (ja) 2013-06-13
NZ602278A (en) 2014-12-24
IL263249A (en) 2018-12-31
IL263253A (en) 2018-12-31
EP3093025A1 (en) 2016-11-16

Similar Documents

Publication Publication Date Title
BR112012023046A2 (pt) vacinas de vírus de febre aftosa recombinantes e seus respectivos usos
BR112017005833A2 (pt) vacinas recombinantes fmdv e seus usos
BR112018004242A2 (pt) composições de vacina que possuem estabilidade e imunogenicidade aumentadas
AR069882A1 (es) Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e
PH12015500092A1 (en) Compositions for immunising against staphylococcus aureus
BR112018015345A8 (pt) Vacinas fmdv vetoriadas de adenovírus recombinante e suas utilizações
MX2009006178A (es) Vacuna contra salmonela.
AR080313A1 (es) Composiciones de virus de moquillo canino (cdv) recombinante y sus usos
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
BR112015008417A8 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
BR112018010494A8 (pt) proteínas de fusão fmdv e e2 e seus usos
BR112014001409A2 (pt) métodos e composições para vacinação contra staphylococcus aureus
BR112016007390A2 (pt) vacina de haemophilus parasuis sorotipo tipo quatro
EA201500140A1 (ru) Ослабленные вакцины от свиного гриппа и способы их получения и применения
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
BR112016012393A8 (pt) vacina, e, uso de uma combinação de um vírus prrs atenuado vivo e um antígeno de lawsonia intracellularis inativado
MX2010008170A (es) Vacunas para influenza canina.
AR089868A1 (es) Vacuna vectorial de eimeria para campylobacter jejuni
UY36328A (es) Vacunas de fmdv recombinante y usos de las mismas
EA201270709A1 (ru) Композиции вакцины и способы их применения
UY33780A (es) ?composiciones y métodos para vacunar ganado vacuno?.
BR102012021810A2 (pt) Xantana como adjuvante em vacina de subunidade recombinante
AR095501A1 (es) Vacunas rsv
TN2010000479A1 (en) Inactivated live - attenuated bluetongue virus vaccine

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B25A Requested transfer of rights approved

Owner name: BIOLEX THERAPEUTICS (US) , MERIAL, INC. (US)

B12F Other appeals [chapter 12.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 7.4 NA RPI NO 2523 DE 14/05/2019 POR TER SIDO INDEVIDA.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/03/2011, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: BIOLEX THERAPEUTICS (US) ; BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. (US)